logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10720230 B1

PDFFull Text
Date of Patent:
Jul. 21, 2020

Filed:

Jun. 12, 2018

Method for administering a checkpoint blockade therapy to a subject

Applicant:

Bostongene Corporation, Lincoln, MA (US);

Inventors:

Feliks Frenkel, Moscow, RU;

Nikita Kotlov, Moscow, RU;

Alexander Bagaev, Moscow, RU;

Maksym Artomov, Kirkwood, MO (US);

Ravshan Ataullakhanov, Moscow, RU;

Assignee:

BostonGene Corporation, Waltham, MA (US);

Attorney:

Wolf, Greenfield & Sacks, P.C.

Primary Examiner:

Pablo S Whaley

Int. Cl.
CPC ...
G16B 45/00 (2019.01); G16H 50/30 (2018.01); C12Q 1/6886 (2018.01); G16H 50/20 (2018.01); G16H 50/70 (2018.01); G06F 16/28 (2019.01); G16B 5/00 (2019.01); G16B 20/00 (2019.01); G16B 40/00 (2019.01); G16B 50/00 (2019.01); G16B 5/20 (2019.01); G06F 17/18 (2006.01); G16H 20/00 (2018.01); G16H 50/50 (2018.01); G16H 20/10 (2018.01); G16H 20/40 (2018.01); G16H 70/20 (2018.01); G16H 10/20 (2018.01);
U.S. Cl.
CPC ...
G16B 45/00 (2019.02); C12Q 1/6886 (2013.01); G06F 16/285 (2019.01); G06F 17/18 (2013.01); G16B 5/00 (2019.02); G16B 5/20 (2019.02); G16B 20/00 (2019.02); G16B 40/00 (2019.02); G16B 50/00 (2019.02); G16H 10/20 (2018.01); G16H 20/00 (2018.01); G16H 20/10 (2018.01); G16H 20/40 (2018.01); G16H 50/20 (2018.01); G16H 50/30 (2018.01); G16H 50/50 (2018.01); G16H 50/70 (2018.01); G16H 70/20 (2018.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01);
Abstract

Techniques for determining whether a subject is likely to respond to an immune checkpoint blockade therapy. The techniques include obtaining expression data for the subject, using the expression data to determine subject expression levels for at least three genes selected from the set of predictor genes consisting of BRAF, ACVR1B, MPRIP, PRKAG1, STX2, AGPAT3, FYN, CMIP, ROBO4, RAB40C, HAUS8, SNAP23, SNX6, ACVR1B, MPRIP, COPS3, NLRX1, ELAC2, MON1B, ARF3, ARPIN, SPRYD3, FLI1, TIRAP, GSE1, POLR3K, PIGO, MFHAS1, NPIPA1, DPH6, ERLIN2, CES2, LHFP, NAIF1, ALCAM, SYNE1, SPINT1, SMTN, SLCA46A1, SAP25, WISP2, TSTD1, NLRX1, NPIPA1, HIST1H2AC, FUT8, FABP4, ERBB2, TUBA1A, XAGE1E, SERPINF1, RAI14, SIRPA, MT1X, NEK3, TGFB3, USP13, HLA-DRB4, IGF2, and MICAL1; and determining, using the determined expression levels and a statistical model trained using expression data indicating expression levels for a plurality of genes for a plurality of subjects, whether the subject is likely to respond to the immune checkpoint blockade therapy.

Find Patent Forward Citations

Quick Actions:

Frenkel, Feliks. (2020). Method for administering a checkpoint blockade therapy to a subject (U.S. Patent No. 10720230). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/10720230

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…